Hacking Pancreatic Cancer: Present and Future of Personalized Medicine.
Hacking Pancreatic Cancer: Present and Future of Personalized Medicine.
复制标题
DOI：
10.3390/ph14070677
复制
发表时间：
2021-07-15
期刊：
影响因子：
--
通讯作者：
Brandi G
中科院分区：
文献类型：
--
作者：
Di Federico A;Tateo V;Parisi C;Formica F;Carloni R;Frega G;Rizzo A;Ricci D;Di Marco M;Palloni A;Brandi G
胰腺癌是一种发病率高、预后差的恶性肿瘤。PC极其复杂的基因组格局对培养肿瘤微环境产生深远影响，从而促进肿瘤生长、耐药性和免疫逃逸机制。尽管在许多类型的癌症的个性化治疗方面取得了显著进展，但化疗仍然是PC治疗的主要手段。奥拉帕尼是第一个在生物标志物选择的人群中显示出显著益处的药物，为个性化方法打开了大门。尽管大量测试靶向药物或免疫疗法的研究未能证明优于标准化疗方案的益处，但一些有趣的药物，单独或与其他药物联合使用，已经取得了有希望的结果。目前正在研究广泛的治疗策略，包括免疫检查点抑制剂酪氨酸激酶抑制剂和靶向代谢途径或肿瘤微环境的药物。在本次综述中，我们的目标是全面概述受PC影响的患者个性化医疗的当前状况和未来方向。
Pancreatic cancer (PC) is a recalcitrant disease characterized by high incidence and poor prognosis. The extremely complex genomic landscape of PC has a deep influence on cultivating a tumor microenvironment, resulting in the promotion of tumor growth, drug resistance, and immune escape mechanisms. Despite outstanding progress in personalized medicine achieved for many types of cancer, chemotherapy still represents the mainstay of treatment for PC. Olaparib was the first agent to demonstrate a significant benefit in a biomarker-selected population, opening the doors for a personalized approach. Despite the failure of a large number of studies testing targeted agents or immunotherapy to demonstrate benefits over standard chemotherapy regimens, some interesting agents, alone or in combination with other drugs, have achieved promising results. A wide spectrum of therapeutic strategies, including immune-checkpoint inhibitors tyrosine kinase inhibitors and agents targeting metabolic pathways or the tumor microenvironment, is currently under investigation. In this review, we aim to provide a comprehensive overview of the current landscape and future directions of personalized medicine for patients affected by PC.
登录
查看更多内容
DOI：
10.1038/nrm.2017.53
发表时间：
2017-10
期刊：
Nature reviews. Molecular cell biology
影响因子：
--
作者：
Ray Chaudhuri A;Nussenzweig A
通讯作者：
Nussenzweig A
DOI：
10.1038/s41571-018-0113-0
发表时间：
2018-12
期刊：
Nature reviews. Clinical oncology
影响因子：
--
作者：
Cocco E;Scaltriti M;Drilon A
通讯作者：
Drilon A
DOI：
10.1056/nejmoa1714448
发表时间：
2018-02-22
期刊：
The New England journal of medicine
影响因子：
--
作者：
Drilon A;Laetsch TW;Kummar S;DuBois SG;Lassen UN;Demetri GD;Nathenson M;Doebele RC;Farago AF;Pappo AS;Turpin B;Dowlati A;Brose MS;Mascarenhas L;Federman N;Berlin J;El-Deiry WS;Baik C;Deeken J;Boni V;Nagasubramanian R;Taylor M;Rudzinski ER;Meric-Bernstam F;Sohal DPS;Ma PC;Raez LE;Hechtman JF;Benayed R;Ladanyi M;Tuch BB;Ebata K;Cruickshank S;Ku NC;Cox MC;Hawkins DS;Hong DS;Hyman DM
通讯作者：
Hyman DM
影响因子：
28.2
作者：
de Bono J;Ramanathan RK;Mina L;Chugh R;Glaspy J;Rafii S;Kaye S;Sachdev J;Heymach J;Smith DC;Henshaw JW;Herriott A;Patterson M;Curtin NJ;Byers LA;Wainberg ZA
通讯作者：
Wainberg ZA
影响因子：
13.8
作者：
Bryant, Kirsten L.;Mancias, Joseph D.;Kimmelman, Alec C.;Der, Channing J.
通讯作者：
Der, Channing J.